Top Markets
#1 Palladium Network Palladium Network +27.90%
#2 Ankr Network Ankr Network +26.55%
#3 BankrCoin BankrCoin +15.90%
#4 Status Status +15.24%
#5 Siren Siren +8.82%
#6 WAX WAX +6.92%
#7 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +6.84%
#8 Wiki Cat Wiki Cat +6.64%
#9 would would +6.14%
#10 Asteroid Shiba Asteroid Shiba +5.16%
Coin of the day
Palladium Network Palladium Network
Settings
Language
ENGLISH
Currency
USD
Theme
Voyager Therapeutics, Inc. Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

VYGR
Rank in Stocks #18067
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating... Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$3.54
Last synced: 2026-09-02
Market Cap
$213.59M
Change (1 day)
3.06%
Change (1 year)
-3.94%
Country
US
Trade Voyager Therapeutics, Inc. (VYGR)

Category

Healthcare
Operating Margin for Voyager Therapeutics, Inc. (VYGR)
Operating Margin as of 2026 TTM: 0.00%
According to Voyager Therapeutics, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Voyager Therapeutics, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.